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Abstract
This case report is based on the clinical observation of a patient with juvenile systemic lupus
erythematosus (SLE) who developed transient galactorrhea. The subsequent literature review
documented an interesting association between prolactin and rheumatic diseases and in particular,
hyperprolactinemia and SLE. The discussion that follows the case report explores this relationship
and proposes a hypothesis regarding why this patient with juvenile SLE developed galactorrhea.
Case report
A 13-year-old girl of Greek origin was initially referred to
the Pediatric Rheumatology clinic at the Montreal Chil-
dren's Hospital with Raynaud's phenomenon affecting
her hands, feet, lips, and tongue. Her past medical history
included intractable epilepsy since the age of two, second-
ary to cortical dysplasia, resulting in refractory complex
partial seizures, despite a partial right frontal lobe resec-
tion and ongoing treatment with anti-convulsant medica-
tions. This situation was complicated by learning
difficulties, behavioral problems, and developmental
delay. Additional significant past medical history
included migraines, precocious puberty and nocturnal
enuresis. Also, she had been mildly anemic for two years
and was found to be iron deficient. At the time of her ini-
tial assessment, her medications included two anti-con-
vulsants, topiramate (sulfamate substituted
monosaccharide) and lamotrigine (phenytriazine class).
She had been taking risperidone 1.5 mg, an anti-psychotic
agent (dopamine antagonist) that was being used during
the school year to control aggressive behavior. Her mother
had discontinued it, two weeks prior to her initial visit to
the Rheumatology clinic, when the diagnosis of juvenile
SLE was made.
Functional inquiry for systemic features of autoimmune
disease was negative for rash, oral ulcers, hair loss, photo-
sensitivity, gastrointestinal disturbances, skin tightening,
muscle weakness, and urinary symptoms. She had begun
menstruating six months prior to her presentation. Her
menstrual periods were regular and lasted 7-9 days with
heavy flow. The family history was significant for "mild"
lupus in her mother.
Physical examination revealed a pleasant and cooperative
adolescent whose weight and height were over the 95th
and 25th percentiles respectively. The remainder of the
exam was unremarkable.
Laboratory investigations revealed that her white blood
cell count was mildly decreased (3.9 × 109/L) with a
decrease in absolute (1.3) and relative neutrophil counts.
She was mildly anemic with a hemoglobin of 107 g/L; her
platelet count was normal. Her erythrocyte sedimentation
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rate (ESR) was elevated at 43 (Winthrobe method) and
her C-reactive protein (CRP) was negative. Urinalysis and
renal function tests were normal. Antinuclear antibody
(ANA) was positive (speckled at 1:160 dilution), extracta-
ble nuclear antigen (ENA) was positive for anti-Sm and
RNP, anticardiolipin antibody (ACLA), as measured by
ELISA (Inova), was positive in both the MPL and GPL frac-
tions (twice the upper limit of normal) and she had a pos-
itive lupus anticoagulant (LAC). Her partial prothrombin
time (PTT) was significantly elevated and she was
Coombs' positive. Complement components C3 and C4
were initially normal but on subsequent evaluations, were
mildly decreased. Her immunoglobulin levels were
within the normal range. She had a significantly elevated
anti-double-stranded DNA binding at 60%. Her thyroid
function was normal and anti-histone antibodies were
negative.
What is the diagnosis and how would you 
manage this patient?
The clinical presentation of this patient was consistent
with systemic lupus erythematosus (SLE). While she ini-
tially fulfilled three American College of Rheumatology
(ACR) criteria for the classification of SLE (1. leukopenia,
2. a positive ANA, and 3. positive antibodies to Sm and
the presence of antiphospholipid antibody (aPL)), she
later developed a non-erosive arthritis thus satisfying the
requirement for four criteria.
While lamotrigine-induced lupus has been described in
the literature [1], our patient differed significantly, from a
serological perspective. The patient with lamotrigine-
induced lupus was anti-Ro/SSA positive and had normal
anti-DNA, anti-phospholipid antibody and complement
levels. In contrast, our patient was anti-Sm positive and
was documented to have elevated anti-dsDNA binding,
which is uncommon in drug-induced lupus. She also had
mildly depressed complement levels at subsequent evalu-
ations, in addition to positive anti-phospholipid antibody
levels.
Similarly, while the induction of LAC by a combination of
valproate and lamotrigine has been described [2], that
patient's GPL was at the cutoff level considered to be pos-
itive and the MPL was normal. In contrast, our patient's
GPL and MPL levels were significantly elevated to approx-
imately twice the upper limit of normal. In addition, anti-
histone antibodies were negative.
The patient met the serologic criteria for antiphospholipid
antibody syndrome (APS). She was positive for both
ACLA and LAC. While approximately 65% of children
with SLE have aPL [3], she lacked the clinical manifesta-
tions of APS having never developed thrombosis and hav-
ing never been pregnant. She was commenced on low-
dose acetylsalicylic acid (ASA) because she was felt to be
at risk for developing thrombosis given that she was doc-
umented to be LAC and ACLA positive. Treatment for APS
in children is variable and has not been systematically
studied [3]. A 2007 study investigated the use of prophy-
lactic aspirin in asymptomatic APL positive adults and
showed no benefit [4]. ASA is frequently used for prophy-
laxis of thrombosis in pediatric SLE patients, although the
evidence in favor of this is lacking.
Additional History
Two weeks later, the patient's mother revealed that the
patient had experienced a milky, non-bloody discharge
from both breasts for the preceding two weeks. There was
no associated discomfort. This lasted approximately two
weeks and stopped without any intervention. There was
no history of trauma, unusual mental or physical stress,
vigorous exercise or recent surgery. The patient was not
sexually active and her beta-HCG was negative. Risperi-
done had been stopped one month before.
What can cause galactorrhea?
Galactorrhea is most frequently caused by hyperprol-
actinemic states as seen in pregnancy, prolactinoma, pri-
mary hypothyroidism, drug-induced hyperprolactinemia
(HPRL) and breast stimulation [5]. Other less common
causes of HPRL include chest wall lesions, renal failure,
hypothalamic-pituitary disease and tuberoinfundibular
stalk disruption [5]. One third of women with HPRL expe-
rience galactorrhea [6] and most women with galactor-
rhea have HPRL [5].
What is the relevance of galactorrhea in 
connective tissue disease?
Prolactin (PRL) is a versatile hormone with many func-
tions including mammary growth, differentiation and lac-
togenesis. It is produced by the anterior pituitary gland
and various extrapituitary sites including endothelial cells
and immune cells. The inter-relationship between PRL
and the immune system is well known [7]. PRL is known
to regulate cellular function including proliferation, dif-
ferentiation, angiogenesis, inflammation, and apoptosis
and is implicated in lymphoproliferation, cytokine pro-
duction and antibody secretion [7]. The human PRL gene
is situated on chromosome 6, close to the major histo-
compatibility complex [7]. PRL is normally released in
repeated pulses as a stress hormone. Levels may be
increased by mental or physical stress, breast stimulation,
vigorous exercise, trauma, surgery under general anesthe-
sia, food ingestion and during sleep [8]. PRL secretion is
under the control of hypothalamic releasing and inhibit-
ing factors and is regulated via inhibition by dopamine
(DA).Pediatric Rheumatology 2009, 7:17 http://www.ped-rheum.com/content/7/1/17
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Research has demonstrated that the endocrine and
immune systems interact in a neuroendocrine immune
loop. As such, rheumatic diseases can manifest endocrine
components. Elevated PRL levels have been found to have
proinflammatory effects [9] and activation of the prolac-
tin receptor (PRL-R) has been shown to lead to the pro-
duction and release of cytokines including IL-1, IL-4, IL-5,
IL-6, IL-10 and INF- [7]. This in turn, stimulates acti-
vated B cells to proliferate and differentiate supporting the
hypothesis that PRL promotes a rupture of tolerance by
stimulating increased immunoglobulin G (IgG) produc-
tion [7]. (Fig. 1) The PRL-R has been identified in a
number of cells and tissues including hematopoietic stem
cells, T and B lymphocytes and almost all subtypes of
immune cells and other important targets in SLE [10].
The first report of HPRL in SLE was in 1987 in male
patients [10]. None of these patients had galactorrhea.
Since then, HPRL (defined as serum PRL greater than 20
ng/ml for men, 25 ng/ml for women) has been reported
in 15-31% of adult SLE patients. This is in contrast to the
much lower frequency of HPRL in healthy women from
14 to 43 years of age of 3% [11]. There is contradictory
data with regard to pre-pubertal SLE patients. Some stud-
ies report normal levels of sex hormones (PRL, follicle-
stimulating hormone (FSH) and luteinizing hormone
(LH), while others have identified from 9-31% of juvenile
SLE patients with HPRL [12]. There has been no report of
galactorrhea in any of the patients with primary HPRL and
SLE.
HPRL in SLE may be explained by the stimulation of pitu-
itary PRL secretion by cytokines. IL-1, IL-6 and other
cytokines have been shown to stimulate release of PRL
and other hormones from cultured rat pituitary cells.
However, it is not well established whether cytokines in
the peripheral blood affect neuroendocrine activity [10].
PRL secretion is inhibited by dopamine, and defects in DA
metabolism have been described in patients with SLE.
Lower levels of one of the main DA metabolites, homova-
nillic acid (HVA), have been documented in SLE patients
as compared with controls. However, circulating levels of
HVA do not reflect DA metabolism in the CNS [13]. When
the DA antagonist metoclopramide was given in vivo to
SLE patients, increased pituitary PRL responsiveness was
demonstrated. This suggests that SLE patients have aug-
mented functional dopaminergic tone and that they dis-
play more physiologic PRL inhibition than healthy
controls [13].
Immune cells produce PRL under normal circumstances
regulated by a tissue-specific mechanism, different from
that controlling pituitary PRL synthesis [13]. T lym-
phocytes from patients with active SLE produce increased
amounts of PRL as compared with controls [13]. Single
nucleotide polymorphisms across the PRL extrapituitary
promoter region have been associated with a relative over-
expression of the PRL gene in SLE [14]. Research has
shown that under unusual circumstances, such as in hypo-
physectomized animals, this extrapituitary PRL can be
"exported" in significant amounts to the general circula-
Neuroendocrine immune interaction as proposed by Blanco-Favela et al. [12] Figure 1
Neuroendocrine immune interaction as proposed by Blanco-Favela et al. [12]
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tion to fulfill biological functions [13]. Therefore, it is
possible that the excess PRL seen in HPRL SLE patients is
not coming from the pituitary, but rather, from the
immune system.
Experimental evidence from animal models supports a
role for PRL in autoimmune diseases. It has been pro-
posed that HPRL may accelerate autoimmunity [12], may
be associated with the development of SLE, and has been
associated with clinical disease activity of SLE during preg-
nancy [10]. Clinical trials using bromocriptine to inhibit
PRL secretion by the pituitary gland in SLE patients have
demonstrated improvement in their clinical course [12]
and flares in disease activity have been reported after its
withdrawal [10]. HPRL in SLE has been correlated with
increased disease activity as measured by SLE disease
activity index (SLEDAI), with active neuropsychiatric
lupus, active lupus nephritis, raised ESR, anemia, lympho-
penia, thrombocytopenia, and hypocomplementemia.
Also, it has been associated with enhanced synthesis of
ANAs, anti-dsDNA, ACLAs, and responsiveness to therapy
[10].
Anti-prolactin antibodies (-PRL Abs) have been reported
in approximately 5% of adult SLE patients [10] and 6% of
pediatric SLE patients [12]. The major isotype of the -
PRL Abs was IgG [9]. Forty percent of SLE patients with
idiopathic HPRL have been documented to have -PRL
Abs with significantly higher PRL levels than SLE patients
without these antibodies [12]. Furthermore, 100% of SLE
patients with -PRL Abs have HPRL [11].
The factors which cause the production of -PRL Abs in
SLE are not well understood. The presence of -PRL Abs
has not been shown to correlate with disease activity as
measured by the SLEDAI [11]. One study found that the
PRL-IgG complex exerted complete biological action in
vitro in samples from patients with idiopathic HPRL [15].
This was measured with the Nb2 lymphoma cell assay
which is an in vitro assay on a specific cell line that specif-
ically assesses the bioactivity of PRL. In contrast, the PRL-
IgG complex may not exert much action in vivo as it does
not readily cross the capillary walls because of its high
molecular weight. This might explain why SLE patients
with HPRL and -PRL Abs do not usually develop clinical
manifestations such as amenorrhea and galactorrhea [12].
-PRL Abs may act in HPRL by inducing a secondary form
of PRL. Two possible mechanisms have been suggested:
First, free PRL is readily filtered by the glomerulus but the
larger PRL-Ab complex could escape degradation in the
kidney. A second mechanism that has been proposed is
that the -PRL Ab could block the autoregulatory feed-
back mechanisms, resulting in presentation of an appar-
ently false low level of serum PRL to the hypothalamus
and pituitary [11]. (See Fig. 1)
A 2001 study of a pediatric population with SLE found
idiopathic HPRL in 31% of their participants [12]. This
was comparable to the incidence found in adult SLE and
as in adults, it was more common in females than in
males. There was a statistically significant positive correla-
tion between serum PRL levels and disease activity and
HPRL and disease activity as measured by the SLEDAI.
There was no correlation between -PRL Abs and disease
activity [12]. This data can be compared with older studies
that found a 9% frequency of HPRL in pediatric SLE [16].
This discrepancy can be explained by differences in the
patients' ages or in PRL measurement technique [12].
Pediatric HPRL SLE patients without -PRL Abs have
reported varying menstrual abnormalities including pri-
mary and secondary amenorrhea. SLE patients with
autoantibodies against PRL did not report these abnor-
malities [12]. Most adult SLE patients with HPRL do not
show expected abnormalities such as menstrual distur-
bances and galactorrhea [12].
What caused this patient's galactorrhea?
Potential causes for galactorrhea in this patient were
excluded such as pregnancy, prolactinoma (the MRI dem-
onstrated a prominent pituitary gland, without any focal
abnormalities), renal failure (normal renal function tests
and urinalysis), hypothalamic-pituitary disease (normal
gonadotropin levels), and primary hypothyroidism (nor-
mal T4, TSH). There were no abnormalities noted on the
ophthalmologic examination of the visual fields.
Although the patient had taken risperidone regularly for
8-9 months, it had been discontinued one month prior to
the onset of galactorrhea. Risperidone, a dopamine antag-
onist is known to induce HPRL, however, the mean half-
life of risperidone and its active metabolite, 9-hydroxyris-
peridone, is 20 hours with a range from 21 to 30 hours.
Due to its short half-life and the fact that the medication
had been discontinued approximately one month prior to
developing galactorrhea, make it unlikely that risperidone
was the cause. Furthermore, there is limited evidence from
a study of healthy volunteers that demonstrated reduction
of the total active moiety of risperidone, when adminis-
tered in combination with topiramate, as in this case [17].
The patient's serum prolactin level (7.5 ug/ml) was within
normal limits and was measured on a single sample at the
time that the patient's galactorrhea was resolving. Due to
the transient nature and spontaneous resolution of galac-
torrhea in this patient, further prolactin levels were not
obtained at that time. Even so, such documentation may
be difficult since prolactin is released in pulses and levels
vary with circadian rhythms and the menstrual cycle so itPediatric Rheumatology 2009, 7:17 http://www.ped-rheum.com/content/7/1/17
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is recommended that repeated samples be obtained in
resting patients [8]. Furthermore, heterophilic antibodies
from human serum can react with the immunoglobulins
included in the assay thereby interfering with the in vitro
immunoassay [18]. Thus, a single normal result does not
rule out transient HPRL as the cause of this patient's galac-
torrhea.
In conclusion, there is a well-established relationship
between PRL and the immune system and specifically, in
patients with SLE. However, galactorrhea has not previ-
ously been reported in these patients. In this case, it was
likely due to multifactorial influences in this patient. Her
previous history of cortical dysplasia gives rise to the pos-
sibility that there are subtle structural and possibly func-
tional abnormalities affecting the pituitary gland.
Previous treatment with a dopamine antagonist may have
sensitized an otherwise clinically quiescent state, within
the context of a potentially hyperprolactinemic state,
given the diagnosis of SLE.
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